abrdn plc Sells 24,723 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

abrdn plc trimmed its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 15.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 136,424 shares of the company's stock after selling 24,723 shares during the period. abrdn plc owned about 0.14% of Neurocrine Biosciences worth $15,719,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. RFP Financial Group LLC raised its stake in shares of Neurocrine Biosciences by 346.5% during the 1st quarter. RFP Financial Group LLC now owns 192 shares of the company's stock worth $26,000 after purchasing an additional 149 shares in the last quarter. Ashton Thomas Private Wealth LLC acquired a new stake in Neurocrine Biosciences in the second quarter valued at approximately $28,000. Innealta Capital LLC bought a new stake in Neurocrine Biosciences in the second quarter worth approximately $30,000. New Covenant Trust Company N.A. acquired a new position in shares of Neurocrine Biosciences during the 1st quarter worth $32,000. Finally, EdgeRock Capital LLC bought a new position in shares of Neurocrine Biosciences during the 2nd quarter valued at $35,000. Institutional investors and hedge funds own 92.59% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have commented on NBIX shares. Piper Sandler raised shares of Neurocrine Biosciences from a "neutral" rating to an "overweight" rating and increased their target price for the stock from $131.00 to $159.00 in a research report on Thursday, August 29th. Jefferies Financial Group raised their price objective on Neurocrine Biosciences from $177.00 to $189.00 and gave the company a "buy" rating in a research note on Monday, August 19th. Raymond James reaffirmed an "outperform" rating and set a $155.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, October 10th. Needham & Company LLC reissued a "hold" rating on shares of Neurocrine Biosciences in a research report on Tuesday. Finally, Oppenheimer upped their price objective on shares of Neurocrine Biosciences from $216.00 to $219.00 and gave the stock an "outperform" rating in a report on Friday, August 2nd. Five analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $163.91.

Neurocrine Biosciences Trading Up 1.6 %

NBIX stock traded up $1.94 during trading on Friday, hitting $122.21. The company had a trading volume of 1,512,407 shares, compared to its average volume of 857,556. The company has a fifty day moving average price of $119.77 and a two-hundred day moving average price of $133.49. Neurocrine Biosciences, Inc. has a fifty-two week low of $103.63 and a fifty-two week high of $157.98. The company has a market cap of $12.37 billion, a P/E ratio of 32.76 and a beta of 0.35.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its earnings results on Wednesday, October 30th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.47 by ($0.23). The firm had revenue of $622.10 million during the quarter, compared to analyst estimates of $604.11 million. Neurocrine Biosciences had a net margin of 17.21% and a return on equity of 15.68%. On average, analysts expect that Neurocrine Biosciences, Inc. will post 4.31 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Ingrid Delaet sold 273 shares of the business's stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $147.70, for a total value of $40,322.10. Following the transaction, the insider now directly owns 6,607 shares of the company's stock, valued at $975,853.90. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Ingrid Delaet sold 273 shares of the company's stock in a transaction dated Tuesday, August 6th. The shares were sold at an average price of $147.70, for a total transaction of $40,322.10. Following the transaction, the insider now owns 6,607 shares in the company, valued at $975,853.90. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Matt Abernethy sold 14,100 shares of the firm's stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $150.38, for a total transaction of $2,120,358.00. Following the completion of the sale, the chief financial officer now owns 31,528 shares of the company's stock, valued at $4,741,180.64. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 47,336 shares of company stock valued at $7,063,652. 4.30% of the stock is currently owned by insiders.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.